Is 1784.TWO overvalued or undervalued?

1784.TWO currently has a P/E ratio of 52.48. Relative to the sector average of 26.70, this suggests the stock may be overvalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy BIONET Corp. stock?

BIONET Corp. trades on TWO. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 1784.TWO?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 1784.TWO protect my money against local inflation?

Many investors in Latin America buy international stocks like 1784.TWO to protect their purchasing power. Because 1784.TWO is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 1784.TWO shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 1784.TWO a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 1784.TWO diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks1784.TWO

BIONET Corp.

NT$59.30-NT$0.70-1.17%

TWO / TWD

Market cap

NT$3.0B

P/E

52.5

EPS (TTM)

NT$0.05

Dividend yield

1.49%

Beta

0.47

1Y return

-29.24%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$33M2021

$32M2022

$37M2023

$37M2024

$39M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.12Low
Current ratio4.27
Cash ratio0.44
Net margin3.5%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

1784.TWO52.5
Healthcare sector median26.7
S&P 50022.0

Trades about 97% above its sector, the market expects faster growth.

Ratios

PEG-2.64
Price to book1.53
EPS (TTM)NT$0.05
Payout ratio15,278%
FCF yield18.44%

Range & risk

NT$54.00NT$118.00

Trading in the lower third of its 52-week band

Beta0.47

Profile

What BIONET Corp. actually does

Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking services, encompassing the storage of general stem cells, mesenchymal stem cells, dental stem cells, adipose stem cells, and peripheral blood stem cells combined with immune cells. Beyond its core stem cell preservation, BIONET also conducts genetic testing services. Its product offerings further extend to anti-aging solutions leveraging stem cell technology, alongside its unique ANIKINE series. Additionally, the company is a pioneer in offering Exosome, an innovative cell-free therapeutic approach.

CEO

Qing Yuan Kang

Employees

Headquarters

Taipei, TP

Founded

2007-12-31

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 1784.TWO and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

1784.TWO has a beta of 0.47, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

BIONET Corp.